PCOLCE2

Across TCGA pan-cancer cohorts, PCOLCE2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PCOLCE2 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PCOLCE2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PCOLCE2 expression acts as an unfavorable survival marker.

PDAC, CCRCC, and HNSC are the cancer types where PCOLCE2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.216	0.676	.027	8	view →
CCRCC	DFS	Median	II,III,IV	0.050	0.981	.038	6	view →
HNSC	OS	Quartile	III,IV	0.326	1.000	.024	6	view →
LUAD	OS	Median	II,III,IV	0.878	1.000	.012	5	view →
LSCC	OS	Median	All	0.827	1.000	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PCOLCE2–PDAC (OS)

Open the PDAC breakdown →